



## Mouse anti-CD79a

Cat. No.: BMS005 (16 ml Ready-to-use)

### Instructions for use

#### Intended use

This antibody is designed for the specific localisation of CD79a in formalin-fixed, paraffin-embedded tissue sections. Anti-CD79a antibody is intended for in vitro diagnostic use.

#### Specifications

|                            |                            |
|----------------------------|----------------------------|
| <b>Specificity:</b>        | Anti-human CD79a           |
| <b>Clone:</b>              | JCB117                     |
| <b>Isotype:</b>            | Mouse IgG1 kappa           |
| <b>Species reactivity:</b> | Human +, others not tested |

#### Summary and Description

CD79 is composed of the glycoproteins CD79 $\alpha$  (40 – 45 kDa) and CD79 $\beta$  (37 kDa). Both components form the disulfid-linked heterodimer CD79 (82 – 95 kDa). The B-cell antigen receptor complex is formed via association of CD79a with membrane-bound immunoglobulins.

Expression of CD79a is largely restricted to B-cell lineage. However, CD79a is coexpressed with CD3. According to Pilozzi *et al.* CD79a positive T-lymphoblastic leukemias/lymphomas are also positive for CD3, whereas cases of B-lymphoblastic leukemias/lymphomas are CD3 negative and CD79a positive.

Initially, CD79a exists in precursor B-cells as cyCD79 in the cytoplasm. During the pro B-cell phase expression on the cell surface starts and remains during the whole differentiation. At the beginning of plasma cell differentiation CD79 expression is stopped. Eventually, only a small amount of plasma cells contain CD79a. CD79a is stronger expressed by B-cells of the follicular mantle zone than by cells in the germ centre.

Anti-CD79a antibody of clone JCB117 is helpful for identification of B-cell neoplasias of all stages of maturity.

#### Reagent provided

Mouse monoclonal antibody in buffer with carrier protein and preservative for stabilisation in the following formats:

**Ready-to-use:** 16 ml (Cat. No. BMS005)

#### Dilution of primary antibody

None

#### Storage and handling

The antibody should be stored at 2-8°C without further dilution.

If necessary, dilutions of the antibody should be done with a suitable antibody dilution buffer (e.g. ZUC025 from Zytomed Systems). The diluted antibody should be stored at 2-8°C after use. Stability of this working solution depends on various parameters and has to be confirmed by appropriate controls.

The antibody provided is suitable for use until the expiry date indicated on the label, if stored at 2-8°C. Do not use product after the expiry date. Positive and negative controls should be run simultaneously with all specimens. If unexpected staining is observed which cannot be explained by variations in laboratory procedures and a problem with the antibody is suspected, contact Zytomed Systems' technical support or your local distributor.

#### Precautions

Use through qualified personnel only. Wear protective clothing to avoid contact of reagents and specimens with eye, skin and mucous membranes. If reagents or specimens come in contact with sensitive area, wash with large amounts of water.

Microbial contamination of the reagent must be avoided, since otherwise non-specific staining may occur.

ProClin300 and sodium azide (NaN<sub>3</sub>) are used for stabilisation. Reaction of sodium azide with lead or copper in drainage pipes can result in the formation of highly explosive metallic azides. Discard the antibody solution in a large volume of running water to avoid formation of deposits. A material safety data sheet (MSDS) for the pure substances is available upon request.

## Staining procedure

Refer to the following table for conditions specifically recommended for this antibody. Also refer to detection system data sheets for guidance on specific staining protocols or other requirements.

| Parameters        | Zytomed Systems recommendations                           |
|-------------------|---|
| *Pre-treatment    | Heat Induced Epitope Retrieval (in citrate buffer pH 6.0) |
| *Control tissue   | Tonsils, lymph nodes                                      |
| *Working dilution | None  |
| *Incubation time  | 60 minutes  |

## Quality control

The recommended positive control tissues for this antibody are tonsils and lymph nodes. We recommend carrying out a positive and a negative control with every staining run. Please refer to the instructions of the detection system for guidance on general quality control procedures.

## Troubleshooting

If you observe unusual staining or other deviations from the expected results please read these instructions carefully, refer to the instructions of the detection system for relevant information or contact your local distributor.

## Expected results

This antibody stains positive in the cell membrane and/or the cytoplasm of CD79a positive cells in formalin-fixed, paraffin-embedded tissue sections. Interpretation of the staining results is solely the responsibility of the user. Any experimental result should be confirmed by a medically established diagnostic procedure.

## Limitations of the Procedure

Immunohistochemistry is a complex technique involving both histological and immunological detection methods. Tissue processing and handling prior to immunostaining, for example variations in fixation and embedding or the inherent nature of the tissue can cause inconsistent results (Nadji and Morales, 1983). Endogenous peroxidase, pseudoperoxidase activity in erythrocytes or biotin may cause non-specific staining depending on the detection system used. Tissues containing Hepatitis B Surface Antigen (HBsAg) may give false positive results with HRP (horse radish peroxidase) detection systems (Omata *et al*, 1980). Inadequate counterstaining and mounting can influence the interpretation of the results.

Zytomed Systems warrants that the product will meet all requirements described from its shipping date until the expiry date is reached, if the product is stored and utilised as recommended. No additional guarantees can be given. Under no circumstances shall Zytomed System be liable for any damages arising out of the use of the reagent provided.

## Performance characteristics

Zytomed Systems has conducted studies to evaluate the performance of the antibody for use with a standard detection system. The product has been found to be sensitive and specific to the antigen of interest with minimal or no cross-reactivity.

## Bibliography

Mason DY *et al*. Blood 86:1453-1459, 1995  
Pillozzi E *et al*. J Pathol 186:140-143, 1998  
Nadji M and Morales AR. Ann N.Y. Acad Sci 1983; 420:134-139  
Omata M *et al* Am J Clin Pathol 1980; 73: 626-632  
Bhargava P, *et al* Am J Clin Pathol. 2007; 128:306-13.  
Chu PG, *et al*. Appl Immunohistochem Mol Morphol. 2001; 9:97-106



[www.zytomed-systems.de](http://www.zytomed-systems.de)  
Zytomed Systems GmbH • Anhaltinerstraße 16 •  
14163 Berlin, Germany • Tel: (+49) 30-804 984  
990

## Explanations of the symbols on the product label

Symbols are used in accordance with ISO 15223-1. Further symbols on the product label might be:



GSH07: Warning / Attention

RUO

For Research Use Only